A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 378
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2025 IOL Market Report: Global Analysis for 2024 to 2030, March, 2025
The “2025 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 12 categories of IOLs: commodity monofocal, enhanced monofocal, intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, post-op adjustable, and phakic IOLs. Additionally, 35 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
1/2/2026
BreakingRegulationRetina
US FDA Rejects Outlook’s Lytenava for a Third Time, Citing Lack of Efficacy Evidence
Outlook Therapeutics reported Dec. 31 that the US FDA had issued a third complete response letter rejecting the company’s biologics license application (BLA) for Lytenava, an ophthalmic formulation...
1/2/2026
BiosimilarsBreakingRegulationRetina
US FDA Approves Ranibizumab (Lucentis) Biosimilar from Bioeq, Formycon
Swiss company Bioeq announced Dec. 23 that the US FDA had approved its ranibizumab (Lucentis) biosimilar for all the reference product’s indications: wet age-related neovascular macular degeneratio...
1/2/2026
BreakingRegulationThyroid Eye Disease
US FDA Accepts Viridian’s TED Candidate for Priority Review, Sets PDUFA Date of June 30, 2026
Viridian Therapeutics reported Dec. 22 that the US FDA had accepted its biologics license application (BLA) for veligrotug, the company’s intravenous treatment candidate for thyroid eye disease (TE...
1/2/2026
BiosimilarsBreakingRetina
Alvotech, Teva Reach Deal with Regeneron to Bring Eylea Biosimilar to US Market No Later than H2-2026
Alvotech and Teva reported Dec. 19 that they had reached a settlement and license agreement with Regeneron that clears the way for Teva to commercialize AVT06, a biosimilar to Eylea, in the US, if ...
1/2/2026
BreakingCornealGlaucomaRegulation
CMS Issues Billing Codes for Cellution’s Allograft, Balance’s Pressure Goggles
The US Centers for Medicare and Medicaid Services (CMS) issued a Q-code in Q3-2025 for Cellution Biologics’ AmchoMatrixDL, an amnion membrane allograft that acts as a barrier and provides protectiv...
1/2/2026
BreakingClinical TrialCornealDry EyeRegulation
US FDA Gives Green Light to Trial of Viatris’ Gene Therapy Candidate for NK
Viatris reported on Dec. 18 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of MR-146, a gene therapy candi...
1/2/2026
BreakingRetinaStudy
Virtual Retina Could Help Unlock New Treatments for Vision Loss, Researchers Say
New computer modeling could help scientists better understand how the retina regenerates, opening the door to new treatments for vision loss, researchers from the UK’s University of Surrey say. The...
1/2/2026
BreakingClinical TrialRetina
USC Roski Eye Takes Part in Phase IIb Trial of RPE Patch Candidate for GA
Researchers at the University of Southern California Roski Eye Institute reported Dec. 17 that they are taking part in a Phase IIb trial of Regenerative Patch Technologies’ retinal pigmented epithe...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.